Pharmaceutical Technology
AUGUST 17, 2022
Merck (MSD outside North America) has entered a partnership agreement with Orna Therapeutics for discovering, developing and marketing various programmes based on next-generation RNA technology. By self-circularisation, Orna’s oRNA technology makes circular ribonucleic acids (oRNAs) from linear RNAs.
Bio Pharma Dive
APRIL 4, 2022
The FDA has yet to sign off on a third-party packaging and labeling facility that Alnylam planned to help launch its drug, called vutrisiran, meaning an approval decision could come as late as mid-July.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
AUGUST 16, 2022
Merck & Co has ramped up its involvement in the RNA category, partnering with US biotech Orna Therapeutics in a deal valued at up to $3.5 Now, Merck has made its own play, partnering with Orna on its proprietary ‘oRNA’ technology, which stands for circular RNA. billion, including $150 million upfront.
Scienmag
MARCH 9, 2022
— Each simple RNA virus has a genome, its “native RNA.” RIVERSIDE, Calif. This genome dictates how the virus replicates in cells to eventually cause disease. The genome also has the code for making a capsid, the protein shell of a virus that encapsulates the genome and protects it like a nanocontainer.
World of DTC Marketing
DECEMBER 29, 2020
Both the Pfizer and Moderna vaccines copied RNA sequence from the virus genome and found a way to manufacture it at scale with high-level processes and quality control. These vaccines were developed using different “platform technologies” that involve slotting genetic material from the virus into a tried and tested delivery package.
Roots Analysis
OCTOBER 30, 2023
In the past few years, Next Generation RNA therapeutics have emerged as one of the key therapeutic modalities in the modern healthcare industry. These RNA based therapeutics play a crucial role in protein production and regulation of gene functions.
pharmaphorum
DECEMBER 13, 2021
It, too, announced plans to invest $500 million in a new facility in Africa for the production, fill/finish and packaging of mRNA vaccines. Dormitzer comes from Pfizer, where he was chief scientific officer for RNA and viral vaccines for more than six years. The UK firm also recently hired Phil Dormitzer as head of vaccines R&D.
Expert insights. Personalized for you.
147 
Let's personalize your content